Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicentre, randomized controlled trial [Abstract]. Support Care Cancer , 26 (4), 1019–1028 Neuropathy from chemo develops in 30 to 40 percent of those receiving chemotherapy. Here’s what to expect if you develop this side effect. An overview of neurologic complications with platinum and non-platinum chemotherapy drugs, and recommendations for dose modification for platinum and non-platinum chemotherapeutic drugs when neuropathy develops during therapy are provided elsewhere. I am new to this board but felt like I should reply to your post. My husband had folfox and finished up his 12 months in December --last two were without the oxilaplatin due to the neuropathy he was experiencing. the neuropathy has continued to get WORSE after the chemo ended. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110 (9), 2110–2118. 10.1002/cncr.23008 [ DOI ] [ PubMed ] [ Google Scholar ] For CIPN prevention, gabapentinoids show no significant benefits in reducing neuropathy among chemotherapy patients, with evidence being too weak to warrant their use without further study. Based on the current limited evidence, gabapentinoids seem to be beneficial in the treatment of CIPN, but more evidence is required to substantiate this. Unfortunately, it can take many months or even longer to find a treatment that works. Doctors have little guidance to know which ones to start with. That’s why research comparing treatment options is so important — and yet, precious little comparative research on treatments for idiopathic sensory polyneuropathy has been published. Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30–40% of patients treated with neurotoxic chemotherapy will develop CIPN and there is Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage). This review updates a review published in 2014, and previous reviews published in 2011, 2005 and 2000. To assess the analgesic efficacy and adverse effects of Gabapentin, an antiepileptic drug that is structurally related to the neurotransmitter gamma- aminobutyric acid (GABA), has been shown to be effective in treating symptoms from several neuropathic syndromes. When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory rather than motor and include reduced feeling and heightened sensitivity to pressure, pain, temperature, and touch. With the initiation of neuropathy, gabapentin was given at 100 mg twice per day. Clinicians could increase gabapentin to 100 mg 3 times daily if the lower daily dose did not resolve symptoms. The abstract reported there was a disappearance of neuropathy symptoms, which continued even with the use of up to 14 total oxaliplatin doses. Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) affects patients' quality of life and treatment effectiveness. Gabapentinoids, like gabapentin and pregabalin, are often used for CIPN treatment, but their efficacy and safety remain uncertain. Compared with the control group, gabapentin therapy led to a statistically significant better response in patients of each baseline neurotoxicity group. Conclusions. Gabapentin monotherapy seems to be well tolerated and useful for the management of chemotherapy-induced neuropathic pain. Abd-Elsayed et al (2016) presented a series of three cases where treatment with SCS led to marked improvement in otherwise treatment-resistant cases of peripheral neuropathy secondary to HIV, diabetes mellitus, and chemotherapy (see Table I).¹⁹ In one patient with CIPN, SCS leads were placed at T10-T11. On follow-up at 3 months and 2 years Sixty-one ovarian cancer patients who received paclitaxel and carboplatin chemotherapy (6 courses every 3 weeks) were enrolled. CIPN occurred in 78.7% of the patients. CIPN was improved in patients who took gabapentin (Neuropathy symptoms scale: pretreatment vs a month after treatment, p value = 0.027) 56). On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN). When peripheral neuropathy occurs due to chemotherapy treatment, it is termed Chemotherapy-induced peripheral neuropathy (CIPN) [1], [2], [5]. CIPN is a frequent adverse effect of anticancer agents most commonly presenting with sensory symptoms more than motor symptoms in a symmetrical “glove and stocking” distribution [3], [4], [5], [6]. Paclitaxel and carboplatin treated patients may benefit from gabapentin therapy in chemotherapy-induced peripheral neuropathy. Chemotherapy substantially deteriorates the neurologic condition of the patients and the quality of life. Compared with the control group, gabapentin therapy led to a statistically significant better response in patients of each baseline neurotoxicity group. Conclusions: Gabapentin monotherapy seems to be well tolerated and useful for the management of chemotherapy-induced neuropathic pain.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |